Penumbra, which markets devices for the treatment of strokes and other vascular conditions, raised $120 million by offering 4.0 million shares at $30.
It had originally planned to offer 3.8 million shares at a range of $25 to $28.
Penumbra plans to list on the NYSE under the symbol PEN. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.
